"The U.S. Food and Drug Administration announced it is fast-tracking the review and approval process for three companies studying psilocybin, the active psychedelic compound in magic mushrooms, and methylone, an MDMA-like molecule, as treatments for depression and post-traumatic stress disorder (PTSD)."
"The FDA also approved a phase 1 clinical trial of noribogaine hydrochloride, a form of the psychoactive substance ibogaine, which has shown some efficacy in treating substance use disorders."
"Ibogaine is extremely difficult to study in the U.S. because it is classified as a Schedule I drug, the most restrictive category, reserved for drugs with the highest abuse potential."
The FDA is accelerating the review process for three companies studying psilocybin and methylone as potential treatments for depression and PTSD. Psilocybin is being investigated for treatment-resistant depression and major depressive disorder, while methylone is focused on PTSD. Additionally, the FDA approved a phase 1 clinical trial for noribogaine hydrochloride, which may help with substance use disorders. Ibogaine, classified as a Schedule I drug, poses challenges for study due to its abuse potential and associated health risks.
Read at www.scientificamerican.com
Unable to calculate read time
Collection
[
|
...
]